SAN FRANCISCO, CA, Culture Biosciences, a company enabling biotech firms to develop and scale manufacturing processes in the cloud, announced a Series B financing of $80 million.
The round was led by Northpond Ventures. Synthesis Capital also participated in the round. Existing investors Cultivian Sandbox Ventures, The Production Board, Craft Ventures, E14 Fund, Box Group, Verily Life Sciences, and Section 32 also contributed. Andrew Lee, Ph.D., of Northpond Ventures will join Culture's Board of Directors.
Culture Biosciences is a technology company in South San Francisco, CA, offering biotechnology companies an easier, faster, and cheaper way to do biomanufacturing R&D. By leveraging Culture's cloud bioreactor platform, bioprocess scientists can spend more time designing and analyzing experiments. Culture's cloud bioreactors offer full control of experimental design and allow real-time monitoring and process changes. Beyond generating data more quickly, Culture's platform provides advanced data visualization and analytics tools to generate new insights into bioprocesses. Learn more here about career opportunities at Culture and our team's passion for solving the world's biomanufacturing capacity problem.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
